China SFDA Okays Commercial Production Of Bird Flu Vaccine
This article was originally published in PharmAsia News
China's State FDA gave its approval to Sinovac Biotech to begin producing its avian influenza vaccine for humans. The Beijing-based company's general manager said the firm is able to produce new H5N1 vaccines as the virus mutates in humans. The SFDA intends for the vaccine to be on hand in time for the Olympics in Beijing this summer. The agency used a first-time procedure that allows it to approve commercial production at the same time it approves a drug license. Initial supplies of the vaccine are to be held in reserve by the government in case of a major bird flu outbreak. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.